Revolutionizing the Manufacturing of Antibody-Drug Conjugates - A Conversation with ADC Bio's Charlie Johnson

Revolutionizing the Manufacturing of Antibody-Drug Conjugates - A Conversation with ADC Bio's Charlie Johnson

0 0 hace 5 meses
24 Sesiones 24 Descargas
In this edition of The Onco’Zine Brief Peter Hofland talks with Charlie Johnson, Chief Executive Officer of ADC Bio, a biotechnology company, specialized in the development of Antibody-drug Conjugates.

Antibody-drug Conjugates, also known as ADCs, are a novel type of targeted anticancer agents. Today 4 drugs in this class of drugs have been approved by regulators around the world, but there are more than 150 investigational agents in this class of drugs in development.

The antibody used ... Más informaciones

Síguenos en Facebook

Copyright 2019 - Spreaker Inc. a Voxnest Company - Crea un podcast - New York, NY
Help